Michel Vounatsos → Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highly controversial approval of Aduhelm, and the calamitous rollout that followed, proved to...
